Injecting hope into the veins of pharmaceutical (pharma) companies in India, work on non-Covid vaccines slowly gathers pace in the country. Several pharma firms have approached the drug regulator, seeking permission to conduct clinical trials.
As a result of the pandemic, regulatory work on non-Covid vaccine proposals hit the skids last year.
In July and August, a subject expert committee on vaccines met and cleared several proposals, including marketing authorisations granted to Bharat Biotech’s influenza vaccine, GlaxoSmithKline’s (GSK's) rotavirus vaccine, among others.
The expert panel also allowed biotechnology and biopharma firms like the Serum Institute of India, Sanofi, and GSK to start Phase 3 clinical trials of their inactivated Salk polio vaccine, hexavalent vaccine (paediatric vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B), quadrivalent influenza, and the herpes zoster vaccines.
Some firms like Biological E were allowed to manufacture the measles vaccine for export only. Cadila Healthcare and Biological E were allowed to start Phase 4 trials of their typhoid and influenza vaccines, respectively.
“Work on Covid vaccines was prioritised for obvious reasons. Many pharma players found it difficult to start trials on non-Covid vaccines during a pandemic, especially when recruiting volunteers or their regular monitoring. Therefore, the proposals seeking approvals to conduct trials were fewer,” said a senior executive of a vaccine firm.
He added that the Central Drugs Standard Control Organisation's (CDSCO's) review process has not yet reclaimed the pre-pandemic levels, and Covid-19 work is still prioritised. But non-Covid work is picking up pace alongside, he said.
The CDSCO had relaxed the stringent requirements needed to adhere to all protocols of a clinical trial last year.
In fact, in a notification in March last year, the CDSCO had said that in the current state it understood the challenges that may arise during conduct of clinical trials.
“This may lead to difficulties in complete adherence to the approved protocol, regulatory provisions, etc. Reiterating that rights, safety, and well-being of trial subjects is of paramount importance, the CDSCO, nonetheless, noted that in some cases, protocol amendment, deviation or modification may be necessary due to unavoidable circumstances,” it had noted.
However, industry sources claimed that with the focus on rolling reviews of Covid vaccine research, reviews of proposals to start clinical trials of non-Covid vaccines were on the back-burner.
“Hardly any fresh approval was given to start new trials. The drug regulator's office and the experts were busy reviewing the real-time data from the Covid vaccine trials,” said another senior executive of a drug firm, which also markets vaccines.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU